Floatz logo

Ny-Eso-1 Tcr Redirected Autologous T Cell Product

Myxoid/Round Cell Liposarcoma

University of PennsylvaniaCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Myxoid/Round Cell Liposarcoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Sotio Biotech Inc.
Phase 1/2CCC
Cyclophosphamide
Sotio Biotech Inc.
Phase 1/2CCC
gpc3-car-t cells
Sotio Biotech Inc.
Phase 1/2CCC
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
USWM CT, LLC
Phase 1CC

Same molecule, other indications

Ny-Eso-1 Tcr Redirected Autologous T Cell Product is also rated in:

metastatic melanomaDormant
CC
Indicative ·
43 / 100
View asset →
synovial sarcomaDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →